GeoVax Advances Toward European Approval for Mpox Vaccine Following EMA Guidance
GeoVax Labs, Inc. has received positive Scientific Advice from the European Medicines Agency, paving the way for expedited approval of its GEO-MVA Mpox vaccine in the EU, potentially accelerating revenue generation.
GeoVax Labs, Inc. has underscored the strategic and commercial importance of the European Medicines Agency's (EMA) positive Scientific Advice for its GEO-MVA vaccine aimed at combating Mpox and smallpox. This regulatory feedback suggests that a single Phase 3 immuno-bridging trial could suffice for a Marketing Authorization Application in the EU, significantly cutting down development time and risk.
The EMA's guidance allows GeoVax to bypass Phase 1 and 2 clinical trials, positioning the company for earlier commercialization and revenue in one of the largest vaccine markets. David Dodd, GeoVax's Chairman and CEO, highlighted this as a potential commercial turning point, with the Phase 3 trial in preparation and global demand for Mpox vaccines on the rise.
Key advantages include a de-risked development path, a market timing aligned with the World Health Organization's recent Mpox public health emergency declaration, and the opportunity to become a first-mover with an MVA-based Mpox vaccine alternative to Bavarian Nordic's Imvanex/Imvamune. GeoVax is also focusing on manufacturing readiness and engaging with European stakeholders to facilitate GEO-MVA access and funding.
This development not only shortens GeoVax's path to revenue but also elevates its profile from a development-stage biotech to a near-term commercial vaccine contender. The company is preparing to initiate its Phase 3 trial in the second half of 2026, leveraging its current production capabilities and planning a transition to a more scalable manufacturing process.